Abstract
Objective: The objective of this study was to test the superiority of multidisciplinary approach, that is, Short-Term Psychodynamic Psychotherapy (STPP) plus drug of choice, versus monotherapy, that is, OnabotulinumtoxinA (OnaBoNT-A). Method: We consecutively recorded data from chronic migraine (CM) patients, with or without medication overuse headache (MOH), who underwent STPP or OnaBoNT-A, with a 3-month follow-up schedule. Headache days and analgesics intake were monitored as primary outcome measures. Propensity score matching (PSM) was used to eliminate discrepancies between groups. Discriminant function analysis (DFA) was used to pinpoint predictive factors associated with the clinical response. Results: 96 patients with CM (64% with MOH) were treated with STPP and 54 (59% with MOH) with OnaBoNT-A. At baseline, OnaBoNT-A patients had more failed preventive therapies, more years of illness and chronicity, and were older; STPP patients were more depressed and had a higher HIT-6. Both STPP and OnaBoNT-A patients showed a significant reduction of headache days (STPP: −14 vs. OnaBoNT-A:−14.3) and analgesics intake (STPP: −12,3 vs. OnaBoNT-A −13.5 pills/month), respectively. MOH diminished more in STPP, adherence was higher in OnaBoNT-A. Results were confirmed after PSM balancing of the groups for those variables that resulted as different (but age). Conclusion: OnaBoNT-A monotherapy produced similar results to psychotherapy plus medication, after correcting for baseline differences.
References
1.
Dodick
DW
. Clinical practice. Chronic daily headache
. N Engl J Med
. 2006 Jan
;354
(2
):158
–65
. .2.
Diener
HC
, Holle
D
, Solbach
K
, Gaul
C
. Medication-overuse headache: risk factors, pathophysiology and management
. Nat Rev Neurol
. 2016 Oct
;12
(10
):575
–83
. .3.
Blumenfeld
AM
, Bloudek
LM
, Becker
WJ
, Buse
DC
, Varon
SF
, Maglinte
GA
, Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)
. Headache
. 2013 Apr
;53
(4
):644
–55
.4.
Buse
DC
, Manack
A
, Serrano
D
, Turkel
C
, Lipton
RB
. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers
. J Neurol Neurosurg Psychiatry
. 2010 Apr
;81
(4
):428
–32
. .5.
Ansari
H
, Ziad
S
. Drug-drug interactions in headache medicine
. Headache
. 2016 Jul
;56
(7
):1241
–8
. .6.
Gaul
C
, Liesering-Latta
E
, Schäfer
B
, Fritsche
G
, Holle
D
. Integrated multidisciplinary care of headache disorders: a narrative review
. Cephalalgia
. 2016 Oct
;36
(12
):1181
–91
. .7.
Viganò
A
, Toscano
M
, Puledda
F
, Di Piero
V
. Treating chronic migraine with neuromodulation: the role of neurophysiological abnormalities and maladaptive plasticity
. Front Pharmacol
. 2019
;10
:32
. .8.
Viganò
A
, Torrieri
MC
, Toscano
M
, Puledda
F
, Petolicchio
B
, Sasso D’Elia
T
, Neurophysiological correlates of clinical improvement after greater occipital nerve (GON) block in chronic migraine: relevance for chronic migraine pathophysiology
. J Headache Pain
. 2018 Aug
;19
(1
):73
.9.
Luedtke
K
, Allers
A
, Schulte
LH
, May
A
. Efficacy of interventions used by physiotherapists for patients with headache and migraine-systematic review and meta-analysis
. Cephalalgia
. 2016 Apr
;36
(5
):474
–92
. .10.
Lilliengren
P
, Johansson
R
, Town
JM
, Kisely
S
, Abbass
A
. Intensive short-term dynamic psychotherapy for generalized anxiety disorder: a pilot effectiveness and process-outcome study
. Clin Psychol Psychother
. 2017 Nov
;24
(6
):1313
–21
. .11.
Town
JM
, Abbass
A
, Driessen
E
, Luyten
P
, Weerasekera
P
. Updating the evidence and recommendations for short-term psychodynamic psychotherapy in the treatment of major depressive disorder in adults
. Can J Psychiatry
. 2017 Jan
;62
(1
):73
–4
. .12.
Abbass
A
, Kisely
S
, Kroenke
K
. Short-term psychodynamic psychotherapy for somatic disorders. Systematic review and meta-analysis of clinical trials
. Psychother Psychosom
. 2009
;78
(5
):265
–74
. .13.
Altieri
M
, Di Giambattista
R
, Di Clemente
L
, Fagiolo
D
, Tarolla
E
, Mercurio
A
, Combined pharmacological and short-term psychodynamic psychotherapy for probable medication overuse headache: a pilot study
. Cephalalgia
. 2009 Mar
;29
(3
):293
–9
.14.
Aurora
SK
, Dodick
DW
, Turkel
CC
, DeGryse
RE
, Silberstein
SD
, Lipton
RB
, OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
. Cephalalgia
. 2010 Jul
;30
(7
):793
–803
.15.
Diener
HC
, Dodick
DW
, Aurora
SK
, Turkel
CC
, DeGryse
RE
, Lipton
RB
, OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
. Cephalalgia
. 2010 Jul
;30
(7
):804
–14
.16.
Blumenfeld
AM
, Tepper
SJ
, Robbins
LD
, Manack Adams
A
, Buse
DC
, Orejudos
A
, Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety
. J Neurol Neurosurg Psychiatry
. 2019 Mar
;90
(3
):353
–60
.17.
Gilliéron
E
. Setting and motivation in brief psychotherapy
. Psychother Psychosom
. 1987
;47
(2
):105
–12
. .18.
Gillieron
E
. Short psychotherapeutic interventions (four sessions)
. Psychother Psychosom
. 1989
;51
(1
):32
–7
. .19.
Austin
PC
. An Introduction to propensity score methods for reducing the effects of confounding in observational studies
. Multivariate Behav Res
. 2011 May
;46
(3
):399
–424
. .20.
De Sanctis
R
, Agostinetto
E
, Masci
G
, Ferraro
E
, Losurdo
A
, Viganò
A
, Predictive factors of eribulin activity in metastatic breast cancer patients
. Oncology
. 2018
;94
(Suppl 1
):19
–28
.21.
De Sanctis
R
, Viganò
A
, Giuliani
A
, Gronchi
A
, De Paoli
A
, Navarria
P
, Unsupervised versus supervised identification of prognostic factors in patients with localized retroperitoneal sarcoma: a data clustering and Mahalanobis distance approach
. Biomed Res Int
. 2018
;2018
:2786163
.22.
Viganò
A
, Savastano
E
, Petolicchio
B
, Toscano
M
, De Sanctis
R
, Maestrini
I
, A study of clinical features and risk factors of self-referring emergency department headache patients: a comparison with headache center outpatients
. Eur Neurol
. 2020
;83
(1
):34
–40
.23.
Rothrock
JF
, Adams
AM
, Lipton
RB
, Silberstein
SD
, Jo
E
, Zhao
X
, FORWARD Study: evaluating the comparative effectiveness of onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine
. Headache
. 2019 Nov
;59
(10
):1700
–13
.24.
Rossi
P
, Faroni
JV
, Tassorelli
C
, Nappi
G
. Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial
. J Headache Pain
. 2013 Feb
;14
:10
. .25.
Kalincik
T
, Jokubaitis
V
, Spelman
T
, Horakova
D
, Havrdova
E
, Trojano
M
, Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis
. Mult Scler
. 2018 Oct
;24
(12
):1617
–26
.26.
© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
